Natixis Has $17.84 Million Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Natixis decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 42.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 34,290 shares of the medical research company's stock after selling 25,811 shares during the period. Natixis' holdings in Thermo Fisher Scientific were worth $17,839,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Barrett & Company Inc. bought a new position in shares of Thermo Fisher Scientific during the fourth quarter worth about $28,000. FPC Investment Advisory Inc. bought a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $28,000. Missouri Trust & Investment Co bought a new stake in Thermo Fisher Scientific during the 4th quarter valued at $29,000. Pillar Financial Advisors LLC acquired a new position in Thermo Fisher Scientific during the 4th quarter valued at about $29,000. Finally, Endeavor Private Wealth Inc. acquired a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $30,000. 89.23% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

TMO has been the subject of several research reports. Royal Bank of Canada decreased their target price on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a research note on Thursday. Evercore ISI lowered their price objective on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating on the stock in a research note on Thursday. Barclays reduced their target price on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. Scotiabank upped their price target on Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a "sector perform" rating in a report on Monday, February 3rd. Finally, Morgan Stanley lifted their target price on Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an "overweight" rating in a report on Friday, January 31st. Four investment analysts have rated the stock with a hold rating and nineteen have given a buy rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and an average target price of $618.68.

Thermo Fisher Scientific Stock Down 1.2 %

Shares of Thermo Fisher Scientific stock traded down $5.07 on Thursday, hitting $426.57. 3,661,206 shares of the company traded hands, compared to its average volume of 1,737,439. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a 12-month low of $409.85 and a 12-month high of $627.88. The company has a 50-day moving average price of $491.37 and a 200 day moving average price of $530.03. The company has a market cap of $161.03 billion, a PE ratio of 25.81, a PEG ratio of 2.99 and a beta of 0.86.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The company had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were issued a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.40%. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.39. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.41%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 3,775 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the transaction, the senior vice president now owns 10,816 shares in the company, valued at $5,759,736.32. This trade represents a 25.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $175,677.00. Following the completion of the sale, the executive vice president now owns 16,363 shares of the company's stock, valued at $9,582,009.17. The trade was a 1.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 23,900 shares of company stock worth $13,106,062. Corporate insiders own 0.34% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.